Trium Capital LLP Invests $19.40 Million in Enfusion, Inc. (NYSE:ENFN)

Trium Capital LLP bought a new position in shares of Enfusion, Inc. (NYSE:ENFN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,739,870 shares of the company’s stock, valued at approximately $19,400,000. Enfusion accounts for 2.4% of Trium Capital LLP’s holdings, making the stock its 4th biggest holding. Trium Capital LLP owned 1.35% of Enfusion as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Mackenzie Financial Corp boosted its stake in Enfusion by 4.8% during the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock valued at $322,000 after purchasing an additional 1,434 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Enfusion by 5.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company’s stock worth $289,000 after purchasing an additional 1,567 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Enfusion by 30.2% during the 1st quarter. Harbor Capital Advisors Inc. now owns 10,201 shares of the company’s stock worth $114,000 after buying an additional 2,366 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Enfusion by 19.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,746 shares of the company’s stock valued at $204,000 after purchasing an additional 3,238 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Enfusion by 6.2% in the 1st quarter. Rhumbline Advisers now owns 66,335 shares of the company’s stock valued at $740,000 after purchasing an additional 3,871 shares during the period. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Stock Up 0.5%

Shares of Enfusion stock opened at $10.85 on Wednesday. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80. The company has a 50-day simple moving average of $10.85 and a 200 day simple moving average of $10.91.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.